These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 4143405)

  • 1. [Improvement of the preparation of anti-influenza donor gamma globulin. Report 2. Testing of the immunogenicity of the killed vaccine, purified and concentrated by means of gradient centrifugation].
    Malafeeva LK; Fridman EA; Tentser PS; Geft RA; Sokolov NN
    Tr Leningr Nauchnoissled Inst Epidemiol Mikrobiol; 1973; 42():78-83. PubMed ID: 4143405
    [No Abstract]   [Full Text] [Related]  

  • 2. [Improvement of the preparation of anti-influenza donor gamma-globulin. Report 1. Experience in the cultivation of the killed influenza vaccine, purified and concentrated by means of gradient centrifugation].
    Sokolov NN; Zhukova TIa; Malafeeva LK; Geft RA
    Tr Leningr Nauchnoissled Inst Epidemiol Mikrobiol; 1973; 42():74-7. PubMed ID: 4143404
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation data from experimental series on a killed influenza vaccine purified and concentrated by differential and density gradient centrifugation. I. Laboratory evaluation data].
    Karpukhin GI; Popov IV; Malikova EV
    Tr Inst Im Pastera; 1976; 47():154-6. PubMed ID: 1052580
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experience in the study of the immunogenicity of killed influenza vaccine, purified and concentrated by the method of sorption chromatography].
    Malafeeva LK; Daĭter AB; Peradze TV; Fridman EA; Tentser PS
    Tr Leningr Nauchnoissled Inst Epidemiol Mikrobiol; 1973; 42():67-73. PubMed ID: 4808388
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation data from experimental series on a killed influenza vaccine purified and concentrated by differential and density gradient centrifugation. II. The results of a study of the reactogenic properties of the vaccine].
    Karpukhin GI; Popov IV; Malikova EV
    Tr Inst Im Pastera; 1976; 47():156-9. PubMed ID: 802567
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of influenza vaccine potency by means of a standardized hemagglutination inhibition test.
    Bürki F; Sibalin M
    Dev Biol Stand; 1974; 26():42-8. PubMed ID: 4435307
    [No Abstract]   [Full Text] [Related]  

  • 7. Influenza vaccines purified by zonal ultracentrifugation.
    Filczak K; Semkow R; Wrzos H; Zakrzewski K; Zgorzelska K
    Acta Microbiol Pol A; 1973; 5(3):261-70. PubMed ID: 4769561
    [No Abstract]   [Full Text] [Related]  

  • 8. The immune response to influenza virus. 3. Changes in the avidity and specificity of early IgM and IgG antibodies.
    Webster RG
    Immunology; 1968 Jan; 14(1):39-52. PubMed ID: 4169724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antigenic properties of donor anti-influenza gamma globulin. Report 1. Indirect test of the degradation of mast cells of white rats and study of the antigenic properties of human gamma-globulin].
    Lopatina TP
    Tr Leningr Nauchnoissled Inst Epidemiol Mikrobiol; 1973; 42():52-7. PubMed ID: 4143401
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunogenic and reactogenic properties of inactivated influenza vaccine purified and concentrated by gradient centrifugation].
    Malikova EV; Safonova LS; Zueva LP; Znakova GM
    Tr Inst Im Pastera; 1982; 57():122-3. PubMed ID: 6763376
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antigenic properties of donor anti-influenza gamma-globulina. Report 2. Clinico-laboratory study of the sensitization properties of donor gamma globulin].
    Lopatina TP
    Tr Leningr Nauchnoissled Inst Epidemiol Mikrobiol; 1973; 42():58-61. PubMed ID: 4143402
    [No Abstract]   [Full Text] [Related]  

  • 12. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
    Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
    Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Live influenza vaccine].
    Smorodintsev AA
    Vestn Akad Med Nauk SSSR; 1983; (12):15-21. PubMed ID: 6666315
    [No Abstract]   [Full Text] [Related]  

  • 14. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model.
    Nerome K; Kumihashi H; Nerome R; Hiromoto Y; Yokota Y; Ueda R; Omoe K; Chiba M
    Dev Biol Stand; 1999; 98():53-63; discussion 73-4. PubMed ID: 10494959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.
    Ohba K; Yoshida S; Zahidunnabi Dewan M; Shimura H; Sakamaki N; Takeshita F; Yamamoto N; Okuda K
    Vaccine; 2007 May; 25(21):4291-300. PubMed ID: 17403560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
    Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.
    Holman DH; Wang D; Raja NU; Luo M; Moore KM; Woraratanadharm J; Mytle N; Dong JY
    Vaccine; 2008 May; 26(21):2627-39. PubMed ID: 18395306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
    Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
    Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of the specific activity and sensitizing properties of purified anti-influenza serum].
    Gaĭdamaka MG
    Vrach Delo; 1967 Jan; 1():99-101. PubMed ID: 4184140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.